Foundayo prescriber base grew from 8,000 to 36,000 in one quarter, analyst coverage says

Eli Lilly's oral GLP-1 Foundayo (orforglipron) went from about 8,000 prescribers to roughly 36,000 in a single quarter, according to two September analyses of the company's second-quarter disclosures ^[1][2]. An international rollout is planned for 2027 ^[1][2].

Foundayo is described as a once-daily oral GLP-1 and the first oral GLP-1 with no food or water restrictions ^[1]. One of the two write-ups spells the product "Foundeo" ^[2]; the other uses Foundayo and describes it the same way ^[1]. The two are referring to the same Lilly oral GLP-1, and no source lists a second oral product under either spelling.

The prescriber growth is one of three pillars in the bull case one analyst lays out for Lilly stock, alongside injectable market share and the retatrutide pipeline ^[2]. The same write-up says Mounjaro and Zepbound account for roughly 6 out of 10 total U.S. obesity prescriptions and about 7 out of 10 injectable ones ^[2].

Lilly's broader numbers were strong in the quarter. One analysis puts Q2 2026 revenue at $22.974 billion, up 47.67% year over year, with Mounjaro alone at $9.94 billion, up 91% ^[1]. The other says Q2 revenue grew 48% year over year ^[2]. Both note that Lilly raised full-year 2026 revenue guidance to $85 billion to $87 billion ^[1][2].

The two write-ups disagree on one pricing figure. One says realized U.S. prices fell about 9% excluding rebate adjustments ^[2]; the other says realized prices fell 13% in the quarter ^[1]. Both describe pricing pressure as a risk to the franchise, and both say volume growth has been large enough to offset it so far ^[1][2].

Several things are not established. Neither write-up says what counts as a "prescriber" — for example, whether it means a clinician who wrote at least one Foundayo prescription in the quarter. Neither reports Foundayo prescription volume, fill counts, or revenue. Neither says what share of the 36,000 are primary care clinicians versus specialists. Prescriber counts are a leading indicator and do not by themselves show how many patients are getting the drug.

Why it matters for patients

A wider prescriber base is the difference between a drug being available mostly through specialists and being available through a patient's regular doctor. If the reported increase holds, more clinicians would be able to discuss and write the oral option, which does not require an injection or the timing rules attached to some other oral GLP-1s ^[1].

That does not answer the questions patients usually run into first: whether a given plan covers the drug, what it costs at the counter, and whether a pharmacy has it in stock. On cost, one write-up notes that the Medicare GLP-1 Bridge Program opened access at $50 per month for 20 million eligible Americans as of July 1 ^[1]. Whether commercial insurers follow is not addressed in either source. The analyses also do not report Foundayo's list price, its approved uses, or its supply situation.

Nothing in either write-up indicates a change to how the drug is prescribed, who is eligible for it, or what it costs patients. The prescriber figure is a measure of clinician activity, not of patient access.

What happens next

Lilly has said the Foundayo international rollout is set for 2027 ^[1][2]. The same write-ups point to a retatrutide filing in the first quarter of 2027 ^[1][2]. Separately, Lilly's tirzepatide (Mounjaro and Zepbound) received a label expansion into cardiovascular risk on August 28, 2026 ^[2].

The next hard update on Foundayo prescribing would come with Lilly's report for the quarter ending September 30, 2026; one write-up notes that estimates for that quarter have drawn 13 upward revisions against one downward ^[2]. The exact reporting date is not given in either source, and neither states when Foundayo prescription volume will be disclosed.